Inhibition of insulin receptor signaling by TNF: Potential role in obesity and non-insulin-dependent diabetes mellitus

Cytokine and Growth Factor Reviews

Volumn 7, Issue 2, 1996, Pages 161-173

  Skolnik, Edward Y ^a   Marcusohn, Jerom ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Diabetes; Inhibition; Insulin receptor; Obesity; Signaling; TNF

Indexed keywords

GLUCOSE TRANSPORTER; GLUT-4 PROTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; MESSENGER RNA; PHOSPHOPROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADIPOCYTE; ANIMAL; ATHEROGENESIS; BODY WEIGHT; DOWN REGULATION; DRUG EFFECT; FORECASTING; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INNER CELL MASS; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY; PHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; TARGET CELL;

ANIMALIA; RODENTIA;

EID: 0030206997     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/1359-6101(96)00021-4     Document Type: Short Survey

References (111)

1. 1. Flier JS, Obesity. In Kahn CR and Weir GC, eds. Diabetes Mellitus. Lea and Febiger, Malverne, PA, 1994, 351-362.
2. 2. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992, 15, 318-368.
3. 3. Garvey WT. Glucose transport and NIDDM. Diabetes Care 1992, 15, 396-417.
4. 4. Haring HU, Mehnert H. Pathogenesis of Type 2 diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia 1993, 36, 176-182.
5. 5. Kahn CR. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994, 43, 1066-1084.
6. 6. Birnbaum MJ. The insulin-sensitive glucose transporter. Int Rev Cytol 1992, 13, 239-97.
7. 7. James DE, Piper RC. Targeting of mammalian glucose transporters. J Cell Sci 1993, 104, 607-612.
8. 8. Flier JS. The adipocyte: Storage depot or node on the energy information superhighway? Cell 1995, 80, 15-18.
9. 9. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372, 425-431.
10. 10. Maffei M. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalmus and with mutations in the db locus. Proc Natl Acad Sci USA 1995, 92, 6957-6960.
11. 11. Hallaas JL, Gajiwala KS, Maffei M et al. Weight reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269, 543-546.
12. 12. Frederich RC, Lollmann B, Hamann A et al. Expression of ob mRNA and its encoded protein in rodents. J Clin Invest 1995, 96, 1658-1663.
13. 13. McGarry JD. Does leptin lighten the problem of obesity? Curr Biol 1995, 5, 1342-1344.
14. 14. Pellymounter MA, Cullen MJ, Baker MB et al. Effects of the obese gene product on body regulation in ob/ob mice. Science 1995, 269, 540-543.
15. 15. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse ob protein: evidence for peripheral signal linking adiposity and central neural networks. Science 1995, 269, 546-459.
16. 16. Chen H, Charlat O, Tartaglia LA et al. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice Cell 1996, 84, 491-495.
17. 17. Lee GH, Proenca R, Montez JM et al. Abnormal splicing of leptin receptor in diabetic mice. Nature 1996, 379, 632-635.
18. 18. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83, 1263-1271.
19. 19. Speigelman BM, Choy L, Hotamisligil GS, Graves RA, Tontoniz P. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem 1993, 268, 6823-6826.
20. 20. Spiegelman BM, Hotamisligil GS. Through thick and thin: Wasting, obesity, and TNF-α. Cell 1993, 73, 625-627.
21. 21. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Ann Rev Biochem 1988, 57, 505-518.
22. 22. Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopath. 1990, 55, 157-170.
23. 23. Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991, 3, 143-158.
24. 24. Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-α. J Biol Chem 1991, 266, 21839-21845.
25. 25. Hotamisligil GS, Shargill NS, Spiegleman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993, 259, 87-91.
26. 26. Fiers W. Tumor necrosis factor: characterization at the molecular, cellular and in vivo levels. FEBS Lett 1991, 285, 199-212.
27. 27. Beutler B. TNF, Immunity and Inflammatory Disease: Lessons of the Past Decade. J Invest Med 1995, 43, 227-235.
28. 28. Beutler B, Greenwald D, Hulmes JD et al. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 1985, 316, 552-554.
29. 29. Berendt AR, Simmons DL, Tansey J, Newbold CI, Marsh K. Intracellular adhesion molecule-1 is an endothelial cell adhesion receptor for plasmodium falciparum. Nature 1989, 341, 57-59.
30. 30. Tracey KJ, Vlassara H, Cerami A. Cachectin/TNF. Lancet 1989, 1, 1122-1126.
31. 31. Eckel RH. Insulin resistance: an adaption for weight maintenance. Lancet 1992, 340, 1452-1453.
32. 32. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95, 2111-2119.
33. 33. Vandenabeele P, Declerq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995, 5, 392-399.
34. 34. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83, 793-802.
35. 35. Banner DW, D'Arcy A, Janes W et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation. Cell 1993, 73, 431-445.
36. 36. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992, 13, 151-153.
37. 37. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994, 76, 959-962.
38. 38. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74, 845-853.
39. 39. Itoh, N, Nagata S. A novel protein domain required for apoptosis. J Biol Chem 1993, 268, 10932-10937.
40. 40. Rothe J, Lesslauer W, Lotscher H et al. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364, 798.
41. 41. Erickson S, de Sauvage FJ, Kikly K et al. Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994, 372, 560-563.
42. 42. Pfeffer K, Matsuyama T, Kundig TM et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73, 457-467.
43. 43. Grell M, Scheurich P, Meager A, Pfizenmaier K. TR60 and TR80 tumor necrosis factor-receptors can independently mediate cytolysis. Lympho Cyto Res 1993, 12, 143-148.
44. 44. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993, 268, 18542-18548.
45. 45. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994, 91, 4854-4858.
46. 46. Rothe M, Wong SC, Henzet WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78, 681-692.
47. 47. Hofmann C, Lorenz K, Braithwaite SS et al. Altered gene expression for tumor necrosis factor-alpha and its receptor: during drug and dietary modulation of insulin resistance. Endocrinology 1994, 134, 264-270.
48. 48. Olefsky JM, Nolan JJ. Insulin resistance and non-insulin-dependent diabetes: cellular and molecular mechanisms. Am J Clin Nutr 1995, 61, 980S-986S.
49. 49. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. J Clin Invest 1994, 94, 1714-1721.
50. 50. Granner DK, O'Brien RM. Molecular physiology and genetics of NIDDM. Diabetes Care 1992, 15, 369-388.
51. 51. Polansky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996, 334, 777-783.
52. 52. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994, 269, 1-4.
53. 53. Quon MJ, Guere-Millo M, Zarnowski MJ et al. Tyrosine kinase-deficient mutant human insulin receptors (Metl1 153-1le) overexpressed in transfected rat adipose cells fails to mediate translocation of epitope-tagged GLUT4. Proc Natl Acad Sci USA 1994, 91, 5587-5591.
54. 54. Ebina Y, Araki R, Taira M et al. Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin and antibody stimulated glucose uptake and receptor tyrosine kinase. Proc Natl Acad Sci USA 1987, 84, 704-708.
55. 55. Sun XJ, Wang L-M, Zhang Y et al. Role of IRS-2 in insulin and cytokine signaling. Nature 1995, 377, 173-177.
56. 56. Pawson T. Protein modules and signaling networks. Nature 1995, 373, 573-580.
57. 57. Schlessinger J. SH2/SH3 signaling molecules. Curr Opin Genet Dev 1994, 4, 25-30.
58. 58. Escobedo JA, Navankasattusas S, Kavanaugh WM, Milfray D, Fried VA, Williams LT. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF receptor. Cell 1991, 65, 75-82.
59. 59. Carpenter CL, Duckworth BC, Auger KR, Cohen BS, Schaffhausen BS, Cantley LC. Purification and characterization of PI3-kinase from rat liver. J Biol Chem 1990, 265, 19704-19711.
60. 60. Skolnik EY, Margolis B, Mohammadi M et al. Cloning of PI3-kinase associated p85 using a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 1991, 65, 83-90.
61. 61. Otsu M, Hiles I, Gout I et al. Characterization of two 85 kD proteins that associate with receptor tyrosine kinases, middle T, complexes and PI3 kinase. Cell 1991, 65, 91-104.
62. 62. Hiles I, Otsu M, Volinia S, Fry MJ et al. PI3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 1992, 70, 419-429.
63. 63. Backer JM, Myers MG Jr, Shoelson SE et al. Phosphatidylinositol 3-kinase is activated by association with IRS-1. EMBO J 1992, 11, 3469-3479.
64. 64. Cantley LC, Auger KR, Carpenter C et al. Oncogenes and signal transduction. Cell 1991, 64, 281-302.
65. 65. Araki E, Lipes MA, Patti ME et al. Alternative signalling pathway in mice with targeted disruption of the IRS-1 gene. Nature 1994, 372, 186-190.
66. 66. Tamemoto H, Kadowaki T, Tobe K et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994, 372, 182-185.
67. 67. Okada T, Kawano Y, Sakaibara T, Hazeki O, Ui M. Essential role of PI3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. J Biol Chem 1994, 269, 3568-3573.
68. 68. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Molec Cell Biol 1994, 14, 4902-4911.
69. 69. Quon MJ, Chen H, BLI et al. Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Molec Cell Biol 1995, 15, 5403-5411.
70. 70. Pillay TS, Langlois WJ, Olefsky JM. The genetics of non-insulin dependent diabetes mellitus. Adv Genet 1995, 32, 51-96.
71. 71. Argiles JM, Lopez-Soriano J, Lopez-Soriano FJ. Cytokines and diabetes: The final step? Involvement of TNF-α in both type I and II diabetes mellitus. Hoarm Metab Res 1994, 26, 447-449.
72. 72. Lang CH, Dobrescu C. Sepsis-induced changes in in vivo insulin action in diabetic rats. Am Physio 1989, 257, E301-308. E301-308.
73. 73. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992, 130, 43-52.
74. 74. Hotamisligil GS, Budavari A, Murray D, Spiefelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: Central role of tumor necrosis factor-α. J Clin Invest 1994, 94, 1543-1549.
75. 75. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995, 95, 2409-2415.
76. 76. Stephens JM, Pekala PH. Transcriptional repression of the C/EBP-α and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-α: Regulation is coordinate and independent of protein synthesis. J Biol Chem 1992, 267, 13580-13584.
77. 77. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Speigelman BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1995, 271, 665-668.
78. 78. Friedenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin dependent diabetes mellitus: effect of weight loss. J Clin Invest 1998, 82, 1398-1406.
79. 79. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993, 268, 26055-26058.
80. 80. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor α-induced phosphorylation of insulin receptor substrate-1 (IRS-1): Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 1995, 270, 23780-23784.
81. 81. Chua SC, Chung WK, Wu-Peng X et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996, 271, 994-996.
82. 82. Hurrel DG, Pedersen O, Kahn CR. Alterations in the hepatic insulin receptor kinase in genetic and acquired obesity in rats. Endocrinology 1989, 125, 2454-2462.
83. 83. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, i, 785-789.
84. 84. Chin JE, Liu F, Roth RA. Activation of protein kinase Cα inhibits insulin-stimulated tyrosine phosphorylation of insulin receptor substrate 1. Molec Endocr 1994, 8, 51-58.
85. 85. Tanti KJF, Gremeaux T, van Obberghen E, Le Marchand-Brustel Y. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 1994, 269, 6051-6057.
86. 86. Blaikie P, Immanuel D, Wu J, Li N, Yajnik V, Margolis B. A region in She distinct from the SH2 domain can bind tyrosine phosphorylated growth factor receptors. J Biol Chem 1994, 269, 32031-32034.
87. 87. Kavanaugh WM, Williams LT. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science 1994, 266, 1862-1865.
88. 88. O'Neill TJ, Craparo A, Gustafson TA. Characterization of an interation between insulin receptor substrate 1 and insulin receptor using the two-hybrid system. Molec Cell Biol 1994, 14, 6433-6442.
89. 89. Gustafson TA, He W, Craparo A, Schaub CD, O'Neill TJ. Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Molec Cell Biol 1995, 15, 2500-2508.
90. 90. Isakoff SJ, Yu Y-P, Su Y-C et al. Interaction between the phosphotyrosine binding domain of She and the insulin receptor is required for She phosphorylation by insulin in vitro. J Biol Chem 1996, 271, 3959-3962.
91. 91. Danielsen AG, Liu F, Hosomi Y, Shii K, Roth RA. Activation of protein kinase Cα inhibits signaling by members of the insulin receptor family. J Biol Chem 1995, 270, 21600-21605.
92. 92. Stephens JM, Lee J, Pilch PF. The primary cause of TNF-induced insulin resistance in fat cells is GLUT4 down-regulation. Diabetes 1995, 44, S111A.
93. 93. Hannun Y, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995, 120, 73-77.
94. 94. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994, 77, 325-328.
95. 95. Schutze S, Machleidt T, Kronke M. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukocyte Biol 1994, 56, 533-541.
96. 96. Wiegmann K, Schutze S, Machleidt T, White D, Kronke M. Functional dichotomy of neural and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994, 78, 1005-1015.
97. 97. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cells death and NF-κB activation. Cell 1995, 81, 495-504.
98. 98. Rothe M, Sarma V, VMD, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 1995, 269, 1424-1427.
99. 99. Rothe M, Pan M-G, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculovirus inhibitor of apoptosis. Cell 1995, 83, 1243-1252.
100. 100. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 1995, 81, 479-482.
101. 101. Yao B, Zhang Y, Delikat S, Mathias S, Basu S, Kolesnick R. Phosphorylation of Raf by ceramide-activated protein kinase. Nature 1995, 378, 307-310.
102. 102. Berti L, Mosthaf L, Kroder G et al. Glucose-induced translocation of protein kinase C isoforms in rat-1 fibroblasts is paralleled by inhibition of the insulin receptor tyrosine kinase. J Biol Chem 1994, 269, 3381-3386.
103. 103. Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci 1994, 19, 470-473.
104. 104. Vilcek J, Lee TH. Tumor necrosis factor. J Biol Chem 1991, 266, 7313-7316.
105. 105. Guesdon F, Waller RJ, Saklatvala J. Specific activation of beta-casein kinase by the inflammatory cytokines interleukin 1 and tumor necrosis factor. Biochem J 1994, 304, 761-768.
106. 106. Marcusohn J, Isakoff SI, Rose E, Symons M, Skolnik EY. The GTP-binding protein Rac does not couple PI3-kinase to insulin-stimulated glucose transport. Curr Biol 1995, 5, 1296-1302.
107. 107. Nolan LL, Friedenberg G, Henry R, Reichart D, Olefsky JM. Role of skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. J Clin Endocr Metab 1994, 78, 471-477.
108. 108. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995, 95, 2195-2204.
109. 109. Kanety H, Hemi R, Papa MZ, Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 1996, 271, 9895-9897.
110. 110. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996, 271, 13018-13022.
111. 111. Verheij M, Bose B, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996, 380, 75-79.